hydroxychloroquine has been researched along with Osteonecrosis in 7 studies
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.
Osteonecrosis: Death of a bone or part of a bone, either atraumatic or posttraumatic.
| Excerpt | Relevance | Reference |
|---|---|---|
| " These studies provide a compelling case for a re-evaluation of the long-term use of glucocorticoids in SLE, focusing on minimizing glucocorticoid exposure as part of the strategy to improve long-term outcomes." | 2.55 | It hasn't gone away: the problem of glucocorticoid use in lupus remains. ( Apostolopoulos, D; Morand, EF, 2017) |
| "001), mean daily prednisolone dosage 7." | 1.72 | Epidemiology and risk factors associated with avascular necrosis in patients with autoimmune diseases: a nationwide study. ( Chang, JW; Liu, CS; Lu, JH; Tsai, HL, 2022) |
| "One objective in the treatment of systemic lupus erythematosus (SLE) disease activity is to reduce long-term rates of organ damage." | 1.48 | Comparison of Remission and Lupus Low Disease Activity State in Damage Prevention in a United States Systemic Lupus Erythematosus Cohort. ( Magder, LS; Petri, M, 2018) |
| "Osteonecrosis is common in systemic lupus erythematosus (SLE) and often disabling." | 1.33 | Systemic lupus erythematosus in a multiethnic US cohort (LUMINA): XXIV. Cytotoxic treatment is an additional risk factor for the development of symptomatic osteonecrosis in lupus patients: results of a nested matched case-control study. ( Alarcón, GS; Baethge, BA; Bastian, HM; Calvo-Alén, J; Cepeda, EJ; Fernández, M; Fessler, BJ; González, EB; McGwin, G; Reveille, JD; Roseman, JM; Toloza, S; Vilá, LM, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 3 (42.86) | 24.3611 |
| 2020's | 3 (42.86) | 2.80 |
| Authors | Studies |
|---|---|
| Tsai, HL | 1 |
| Chang, JW | 1 |
| Lu, JH | 1 |
| Liu, CS | 1 |
| Sheha, D | 1 |
| El-Shayeb, M | 1 |
| Eid, Y | 1 |
| Amin, M | 1 |
| Saeed, A | 1 |
| Abdou, D | 1 |
| Aly, T | 1 |
| Samy, S | 1 |
| Elziaty, R | 1 |
| Aboelyazed, S | 1 |
| Osman, A | 1 |
| Sheha, A | 1 |
| Long, Y | 1 |
| Zhang, S | 1 |
| Zhao, J | 1 |
| You, H | 1 |
| Zhang, L | 1 |
| Li, J | 1 |
| Leng, X | 1 |
| Wang, Q | 1 |
| Tian, X | 1 |
| Li, M | 1 |
| Zeng, X | 1 |
| Petri, M | 1 |
| Magder, LS | 1 |
| Joo, YB | 1 |
| Sung, YK | 1 |
| Shim, JS | 1 |
| Kim, JH | 1 |
| Lee, EK | 1 |
| Lee, HS | 1 |
| Bae, SC | 1 |
| Apostolopoulos, D | 1 |
| Morand, EF | 1 |
| Calvo-Alén, J | 1 |
| McGwin, G | 1 |
| Toloza, S | 1 |
| Fernández, M | 1 |
| Roseman, JM | 1 |
| Bastian, HM | 1 |
| Cepeda, EJ | 1 |
| González, EB | 1 |
| Baethge, BA | 1 |
| Fessler, BJ | 1 |
| Vilá, LM | 1 |
| Reveille, JD | 1 |
| Alarcón, GS | 1 |
1 review available for hydroxychloroquine and Osteonecrosis
| Article | Year |
|---|---|
It hasn't gone away: the problem of glucocorticoid use in lupus remains.
Topics: Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Azathioprine; Cardiovascular Diseases; Cata | 2017 |
6 other studies available for hydroxychloroquine and Osteonecrosis
| Article | Year |
|---|---|
Epidemiology and risk factors associated with avascular necrosis in patients with autoimmune diseases: a nationwide study.
Topics: Adrenal Cortex Hormones; Alcoholism; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Male | 2022 |
Unfolding of sickle cell trait by coronavirus disease 2019 (COVID-19) infection.
Topics: Adrenal Cortex Hormones; Anticoagulants; Azithromycin; Combined Modality Therapy; COVID-19; COVID-19 | 2020 |
Risk of osteonecrosis in systemic lupus erythematosus: An 11-year Chinese single-center cohort study.
Topics: Adolescent; Adult; Antibodies, Antiphospholipid; Antirheumatic Agents; China; Cohort Studies; Female | 2021 |
Comparison of Remission and Lupus Low Disease Activity State in Damage Prevention in a United States Systemic Lupus Erythematosus Cohort.
Topics: Adult; Antirheumatic Agents; Cardiomyopathies; Cataract; Cohort Studies; Diabetes Mellitus; Disease | 2018 |
Prevalence, incidence, and associated factors of avascular necrosis in Korean patients with systemic lupus erythematosus: a nationwide epidemiologic study.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antirheumatic Agents; Cohort Studies; Comorbidity; Databases, | 2015 |
Systemic lupus erythematosus in a multiethnic US cohort (LUMINA): XXIV. Cytotoxic treatment is an additional risk factor for the development of symptomatic osteonecrosis in lupus patients: results of a nested matched case-control study.
Topics: Adult; Antibiotics, Antineoplastic; Black or African American; Drug Administration Schedule; Drug Th | 2006 |